Want to see HK:9995 full AI Analyst Report?
9995 Stock Chart & Stats
HK$82.50
-HK$2.00(-2.36%)
At close: 4:00 PM EDT
HK$82.50
-HK$2.00(-2.36%)
Day’s Range― - ―
52-Week RangeHK$63.30 - HK$126.60
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00M
Market Cap
HK$63.09B
Enterprise ValueHK$36.22K
Total Cash (Recent Filing)HK$5.14B
Total Debt (Recent Filing)HK$310.96M
Price to Earnings (P/E)11.1
Beta1.53
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.37
Shares Outstanding208,581,240
10 Day Avg. Volume2,051,282
30 Day Avg. Volume3,001,072
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)10.96
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$116.49Price Target Upside41.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)7.48
Revenue Forecast (FY)HK$7.43B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability InflectionThe sharp TTM improvement in revenue and profitability indicates stronger commercial execution and growing operating scale. If the improved performance persists, higher margins can support internal reinvestment, strengthen the company’s competitive position, and improve the foundation for sustainable growth.
Strong Cash ConversionPositive operating and free cash flow, together with close conversion of earnings into cash, improves the quality of reported profits. This provides greater flexibility to fund drug development and commercialization internally, reducing reliance on external financing while the business expands.
Conservative TTM LeverageLow debt relative to equity gives RemeGen a stronger financial cushion after the recent profitability improvement. A healthier capital structure can reduce financing pressure, preserve capacity for research and commercialization investment, and provide resilience if operating results moderate.
Bears Say
Earnings Sustainability RiskThe rapid reversal from substantial losses to exceptionally strong profitability makes the current earnings base difficult to assess as durable. Such volatility can complicate planning, reduce confidence in forward earnings power, and leave future results sensitive to changes in product performance or revenue timing.
Cash Flow ConsistencyAlthough TTM cash generation is strong, the preceding record shows repeated cash burn and a mismatch between earnings and cash flow. Continued inconsistency could constrain investment capacity, increase dependence on financing, and make the recent cash-flow turnaround less dependable over the next several quarters.
Balance-Sheet Trajectory InstabilityThe large year-to-year changes in debt and leverage indicate that the capital structure can shift materially with operating performance and financing needs. Even with conservative TTM leverage, renewed borrowing or weaker results could reduce flexibility and increase financial risk during development or commercialization.
RemeGen Co. Ltd. Class H News
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$63.30 and its highest was HK$126.60 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$63.09B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Nov 04, 2026 which is in 44 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Aug 24, 2026. The company reported HK$9.711 earnings per share for the quarter.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of HK$9.711 in its last earnings report. Following the earnings report the stock price went down -5.957%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$116.49 (41.20% Upside)
HK$116.49 (41.20% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
9995 Stock 12 Month Forecast
Average Price Target
HK$116.49
▲(41.20% Upside)
Technical Analysis
Akeso, Inc.
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―